SCHEMBL4385832

SCHEMBL4385832

Cc1ccc(CNC(=O)c2csc(CNC(=O)COc3ccc(OC(F)(F)F)cc3)n2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.52
CYP3A4 P08684 3/20 0.52
CYP2C19 P33261 3/20 0.52
CYP2C9 P11712 2/20 0.52
POLB P06746 1/20 0.52
HTT P42858 3/20 0.49
HPGD P15428 3/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
ALDH1A1 P00352 1/20 0.49
SMN1; SMN2 Q16637 2/20 0.48
MAPT P10636 2/20 0.48
CYP2D6 P10635 1/20 0.48
PDE2A O00408 1/20 0.47
ADRB2 P07550 1/20 0.45
SCN10A Q9Y5Y9 1/20 0.45
EPHX2 P34913 1/20 0.44
NR1H4 Q96RI1 1/20 0.44
TRPM8 Q7Z2W7 1/20 0.44
ALOX12 P18054 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4390529 0.93 CYP1A2 (0.62) CYP1A2CYP3A4CYP2C19CYP2C9POLB
SCHEMBL5668242 0.87 CACNA1G (0.51) CYP1A2CYP3A4CYP2C19CYP2C9POLB
SCHEMBL5670152 0.87 CYP1A2 (0.50) CYP1A2CYP3A4CYP2C19CYP2C9POLB
SCHEMBL4389979 0.86 PDE2A (0.49) HPGDALDH1A1MAPTPDE2ATRPM8
SCHEMBL2172869 0.85 CYP1A2 (0.43) CYP1A2CYP3A4CYP2C19CYP2C9POLB
SCHEMBL5667911 0.85 CYP1A2 (0.43) CYP1A2CYP3A4CYP2C19CYP2C9POLB
SCHEMBL5669948 0.85 CYP1A2 (0.47) CYP1A2CYP3A4CYP2C19CYP2C9POLB
SCHEMBL5668972 0.85 NPC1 (0.52) CYP1A2CYP3A4CYP2C19CYP2C9POLB
SCHEMBL5670344 0.85 ALDH1A1 (0.48) CYP3A4CYP2C19CYP2C9POLBHTT
SCHEMBL4392420 0.85 CYP1A2 (0.52) CYP1A2CYP3A4CYP2C19CYP2C9POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2009-07-23 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090186905-A1 ANAPLASTIC LYMPHOMA KINASE MODULATORS AND METHODS OF USE ALK, BCL3, MCL1 CYP1A2 3488/4885CYP3A4 3497/4885CYP2C19 4109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.